Related Experiment Videos
Thalidomide as initial therapy for early-stage myeloma
S V Rajkumar1, M A Gertz, M Q Lacy
1Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Leukemia
|April 12, 2003
Summary
Thalidomide shows significant activity in early-stage multiple myeloma, potentially delaying disease progression. This initial therapy demonstrated notable response rates and progression-free survival in a phase II trial.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Early-stage multiple myeloma patients are typically monitored until symptomatic disease develops.
- There is a high risk of progression to symptomatic multiple myeloma within 1-2 years.
- Current observation strategies may not adequately mitigate the risk of disease advancement.
Purpose of the Study:
- To evaluate thalidomide as an initial therapy for early-stage multiple myeloma.
- To assess the potential of thalidomide to delay progression to symptomatic disease.
- To determine response rates and progression-free survival in patients receiving thalidomide.
Main Methods:
- A phase II trial involving 31 patients with smoldering or indolent multiple myeloma.
- Thalidomide initiated at 200 mg/day, with monthly and then quarterly follow-ups.
- Assessment of partial and minor responses based on serum and urine monoclonal (M) protein reduction.
Main Results:
- Of 29 eligible patients, 34% achieved a partial response (≥50% M protein reduction).
- Including minor responses (25-49% M protein decrease), the overall response rate was 66%.
- Progression-free survival estimates were 80% at 1 year and 63% at 2 years.
Conclusions:
- Thalidomide demonstrates significant activity in early-stage multiple myeloma.
- This therapy has the potential to delay progression to symptomatic disease.
- Further investigation in randomized trials is warranted to confirm these findings.